In COVID-19 clinical update #121, Dr. Griffin discusses age as a risk factor for severe disease, updated vaccine boosters for the fall, pediatric infection and antibody seroprevalence in Arkansas over the first year of the COVID-19 pandemic, all-cause maternal mortality in the United States before and during the pandemic, and the effect of 2-week interruption in methotrexate treatment and how it impacts vaccine immunity. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Age as a risk factor for severe disease (NY Times) Omicron boosters for the fall (NPR) Pediatric infection and antibody seroprevalence in Arkansas (PIDS) All-cause US maternal mortality during pandemic (JAMA) Effect of 2-week interruption in methotrexate treatment (The Lancet) PAXLOVID patient eligibility screening checklist (FDA) Remdesivir fact sheet for providers (Veklury)  Bebtelovimab fact sheet for providers (FDA) PAXLOVID drug interaction checker (IDSA) Contribute to FIMRC fundraiser at PWB 35:42 Dr. Griffin’s treatment guide (pdf) Letters read on TWiV 914 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In COVID-19 clinical update #121, Dr. Griffin discusses age as a risk factor for severe disease, updated vaccine boosters for the fall, pediatric infection and antibody seroprevalence in Arkansas over the first year of the COVID-19 pandemic, all-cause maternal mortality in the United States before and during the pandemic, and the effect of 2-week interruption in methotrexate treatment and how it impacts vaccine immunity.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Age as a risk factor for cases.html">severe disease (NY Times)
• Omicron boosters for the fall (NPR)
• Pediatric infection and antibody seroprevalence in Arkansas (PIDS)
• All-cause US maternal mortality during pandemic (JAMA)
• Effect of 2-week interruption in methotrexate treatment (The Lancet)
• PAXLOVID patient eligibility screening checklist (FDA)
• Remdesivir fact sheet for providers (Veklury) 
• Bebtelovimab fact sheet for providers (FDA)
• PAXLOVID drug interaction checker (IDSA)
• Contribute to FIMRC fundraiser at PWB 35:42
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 914
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv